Subscribe
shutterstock_1816822259_michael_vi
Michael Vi / Shutterstock.com
26 April 2022GenericsMuireann Bolger

BioMarin, MSD sue Aurobindo over rare disease drug

BioMarin Pharmaceutical and MSD (known as 'Merck & Co' in the US), have sued Aurobindo Pharmaceuticals for patent infringement in a dispute over the drug Kuvan (Sapropterin hydrochloride), used to treat a rare genetic disorder.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
MSD hit with €39m fine over contraceptive generic delay
26 October 2022   The probe in Spain centred on the delayed entry of generic versions of a branded contraceptive | The commission found evidence of “unjustified legal action”.
Americas
BioMarin accuses engineer of stealing 1,800 files
23 November 2021   BioMarin Pharmaceuticals has accused a former engineer who went to work for competitor Sangamo Therapeutics of stealing more than 1,800 files containing confidential information and trade secrets.
Americas
Sarepta and Biomarin resolve patent dispute with $35m licence
20 July 2017   Biopharmaceutical company Sarepta Therapeutics and biotech firm Biomarin Pharmaceutical have settled a patent dispute and entered into a licence agreement.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Generics
MSD hit with €39m fine over contraceptive generic delay
26 October 2022   The probe in Spain centred on the delayed entry of generic versions of a branded contraceptive | The commission found evidence of “unjustified legal action”.
Americas
BioMarin accuses engineer of stealing 1,800 files
23 November 2021   BioMarin Pharmaceuticals has accused a former engineer who went to work for competitor Sangamo Therapeutics of stealing more than 1,800 files containing confidential information and trade secrets.
Americas
Sarepta and Biomarin resolve patent dispute with $35m licence
20 July 2017   Biopharmaceutical company Sarepta Therapeutics and biotech firm Biomarin Pharmaceutical have settled a patent dispute and entered into a licence agreement.

More on this story

Generics
MSD hit with €39m fine over contraceptive generic delay
26 October 2022   The probe in Spain centred on the delayed entry of generic versions of a branded contraceptive | The commission found evidence of “unjustified legal action”.
Americas
BioMarin accuses engineer of stealing 1,800 files
23 November 2021   BioMarin Pharmaceuticals has accused a former engineer who went to work for competitor Sangamo Therapeutics of stealing more than 1,800 files containing confidential information and trade secrets.
Americas
Sarepta and Biomarin resolve patent dispute with $35m licence
20 July 2017   Biopharmaceutical company Sarepta Therapeutics and biotech firm Biomarin Pharmaceutical have settled a patent dispute and entered into a licence agreement.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims